EXCE

Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis

LEVERKUSEN, Germany - Biofrontera AG (DSE: B8F) announces todaythat it has received very positive results in the dose finding partof its phase IIb/III clinical trial started in autumn 2006. BF-200ALA, a gel that combines the active substance 5-aminolevulinic acid(ALA) with the nanoemulsion BF-200, was strongly and significantlysuperior to placebo in the treatment of actinic keratosis. BF-...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

Results also show significant additional protection againstinfection with virus types beyond 16 and 18 with the GSK cervicalcancer candidate vaccine PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Resultsfrom an interim analysis of a Phase III study show thatCERVARIX(R), the GlaxoSmithKline cervical cancer candidate vaccine,provides up to 100 percent protection against advanced prec...

Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data

CHAPEL HILL, N.C., May 25, 2007 /PRNewswire/ -- With enormousinvestments and the success of a pharmaceutical product at play,pharmaceutical firms need to develop effective strategies forcommunicating clinical trial results early. Companies that mastertheir communication planning and execution will gain a significantadvantage in the marketplace. According to research and consulting...

Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

Single-Dose Oral Ty800 Vaccine Immunogenic & Well-Toleratedin NIH-Sponsored Phase 1/2 Study NEEDHAM, MA (May 18, 2007) - AVANT Immunotherapeutics, Inc.(Nasdaq: AVAN) announced today positive preliminary results from aninvestigational double-blind, placebo-controlled Phase 1/2dose-escalating clinical trial of its typhoid fever vaccinecandidate, Ty800, in healthy volunteers. The...

Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

NEEDHAM, Mass.--(BUSINESS WIRE)--May 18, 2007 - AVANTImmunotherapeutics, Inc. (Nasdaq: AVAN) announced today positivepreliminary results from an investigational double-blind,placebo-controlled Phase 1/2 dose-escalating clinical trial of itstyphoid fever vaccine candidate, Ty800, in healthy volunteers. Theresearchers found the single-dose, oral vaccine to be welltolerated and immunogenic, wi...

Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke

NICE Appraisal Committee concludes that alteplase is clinicallyand cost effective INGELHEIM/Germany, 14 May 2007 – A new clinical appraisalpublished by the National Institute for Health and ClinicalExcellence (NICE) in the UK has recommended the use of alteplasefor the treatment of patients with acute ischaemic stroke, based onits clinical and cost effectiveness...

Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective

- Phase 3 Patient Enrolment Planned for Second Half of 2007 - BRISBANE, Australia, April 16, 2007 /PRNewswire-FirstCall/ --Progen Pharmaceuticals Limited today announced the final stage 1results of its Phase 2 trial of PI-88 in patients who hadpreviously undergone surgical removal of liver cancer. The 48 weekdata demonstrated that 160 mg of PI-88 showed an improvement indisease-free rate,...